ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2005
Effective and rapid treatment of painful localized transient osteoporosis (bone marrow edema) with intravenous ibandronate.
Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 98 citations in OpenAlex.
- Effect of ibandronate on spontaneous osteonecrosis of the knee: a randomized, double-blind, placebo-controlled trial.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2014Trial
- No Significant Differences between Bisphosphonates and Placebo for the Treatment of Bone Marrow Lesions of the Knee: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Journal of clinical medicine · 2024Review
- The terminologies of transient, migratory, or localized osteoporosis, and bone marrow edema syndrome: a scoping review.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2024Article
- Bone marrow edema of the hip: a narrative review.Archives of orthopaedic and trauma surgery · 2023Review
- Influence of Vitamin D and C on Bone Marrow Edema Syndrome-A Scoping Review of the Literature.Journal of clinical medicine · 2022Article
- Bone marrow oedema syndrome of the foot and ankle in a paediatric population: a retrospective case series with serial MRI evaluation.Journal of children's orthopaedics · 2020Article
- How We Manage Bone Marrow Edema-An Interdisciplinary Approach.Journal of clinical medicine · 2020Article
- Zoledronic acid is more efficient than ibandronic acid in the treatment of symptomatic bone marrow lesions of the knee.Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA · 2020Article
- Single Dose Therapy of Zoledronic Acid for the Treatment of Transient Osteoporosis of Hip.Annals of rehabilitation medicine · 2019Article
- Observational
- Recurrent Migratory Transient Bone Marrow Edema of the Knees Associated with Low Vitamin D and Systemic Low Bone Mineral Density: A Case Report and Literature Review.Case reports in rheumatology · 2018Article
- Transient osteoporosis of the hip: review of the literature.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2017Review
- Risk factors in transient osteoporosis: a retrospective study on 23 cases.Clinical rheumatology · 2016Article
- A case series of pregnancy- and lactation-associated osteoporosis and a review of the literature.Therapeutics and clinical risk management · 2015Article
- Treatment of bone marrow lesions (bone marrow edema).BoneKEy reports · 2015Review
- Transient osteoporosis of the hip: A case report.The Journal of the Canadian Chiropractic Association · 2013Article
- Spontaneous osteonecrosis of the knee (SONK).Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA · 2013Article
- Transient osteoporosis of the hip: successful treatment with teriparatide.Rheumatology international · 2012Article
- Bone marrow lesions: a universal bone response to injury?Rheumatology international · 2012Review
- Treatment of transient osteoporosis of the hip with intravenous zoledronate - a case report -.Annals of rehabilitation medicine · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Localized transient osteoporosis (LTO; bone marrow edema syndrome) is a rare disorder of generally unknown etiology that is characterized by acute onset of disabling bone pain. Treatment options are currently limited and largely ineffective. The locally increased bone turnover and low bone mineral density (BMD) typical of LTO indicate a potential role for bisphosphonate therapy. Ibandronate, a potent nitrogen-containing bisphosphonate, has proven efficacy in the management of postmenopausal osteoporosis and corticosteroid-induced osteoporosis when administered as a convenient intermittent intravenous (i.v.) injection with a between-dose interval of 2 or 3 months. In a study of 12 patients with LTO, ibandronate was administered as an initial 4-mg i.v. dose with a second, optional injection of 2 mg at 3 months. Daily calcium and vitamin D supplements were provided. Pain was measured at baseline and at 1, 2, 3, and 6 months using a visual analog scale (VAS) of 1-10, and BMD was measured at baseline and 6 months. I.v. ibandronate provided rapid and substantial pain relief. The mean (SD) VAS score decreased from 8.4 (1.3) at baseline to 0.5 (0.7) at 6 months, at which time seven patients had achieved complete pain relief. At 6 months, mean lumbar spine BMD had increased by 4.0% (range -0.8 to 7.7%) in the overall population. I.v. ibandronate injection affords advantages over currently available oral and i.v. bisphosphonates and thus offers a promising therapeutic advance in the treatment of LTO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.